Total operating costs +8.5% to $1.64B.
Revenue breakdown: Medical segment +8.2% to $1.06B, Diagnostics +3.1% to $672M. U.S revenues +2.3%, international +8.9%, reflecting strength in emerging markets.
BD raises the lower end of its FY adjusted EPS guidance by 3 cents and now expects $6.19-6.22 vs $5.81 a year earlier. Consensus is for $6.23. BD projects that reported and currency-neutral revenues will increase 4.5-5% vs a previous prediction of +4-5%.
BD intends to buy back $450M of its common stock during the FY. (PR)